This review discusses the evidence in support of the use of oral crizotinib for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Independent commentary by Associate Professor Ben Solomon a Medical Oncologist at the Peter MacCallum Cancer Centre in Melbourne, Australia.
Please login below to download this issue (PDF)